相关临床试验
17
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1789
已完成
17
100.0%
暂无批准数据
- ACTG has initiated study A5402, a phase 2 randomized trial comparing pramipexole to escitalopram for treating depressive disorders with or without mild neurocognitive disorder in people living with HIV. - The study will enroll 186 participants aged 18-70 who are virally suppressed on antiretroviral therapy for at least three months. - Combined depressive disorders and mild neurocognitive disorder affect up to 80 percent of people living with HIV, representing a two- to four-fold increase compared to the general population. - Researchers hope pramipexole, which stimulates dopamine receptors, will prove more effective than traditional serotonin-based antidepressants for these HIV-associated neuropsychiatric conditions.
- The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona and Siemens Healthineers, becomes the first dental-dedicated MRI system to receive FDA clearance in the United States. - Clinical trials validated the system's effectiveness across multiple dental specialties including endodontics, periodontics, TMJ disorders, tooth extraction, and orthodontics with radiation-free imaging capabilities. - The ddMRI system demonstrates ability to differentiate active inflammation from healthy tissue, assess tooth pulp vitality non-invasively, and visualize dental structures with advanced soft tissue contrast in under 20 minutes. - This breakthrough technology addresses diagnostic limitations of current imaging modalities by providing superior soft tissue characterization without ionizing radiation exposure.
- Tonix Pharmaceuticals completed a $20 million registered direct offering with Point72, selling 615,025 shares at $16.26 per share to fund commercialization and development activities. - The company will use proceeds to support its marketed fibromyalgia treatment TONMYA, the first FDA-approved prescription medicine for fibromyalgia in over 15 years. - Tonix's diverse pipeline includes treatments for central nervous system disorders, immunology, rare diseases, and infectious diseases, with several candidates in Phase 2-ready status. - The funding will also support development of TNX-2900 for Prader-Willi syndrome, expected to begin a potential pivotal Phase 2 study in 2026.
- The SLIM LIVER study demonstrated that semaglutide significantly improved cardiovascular risk biomarkers in people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). - This Phase II trial represents the first clinical study to test semaglutide as a treatment for MASLD specifically in HIV patients, addressing a population at increased cardiovascular risk. - The cardiovascular improvements appeared independent of changes in weight, liver fat, or insulin resistance, suggesting semaglutide has additional protective mechanisms beyond its known metabolic effects. - Results were presented at the 2025 AASLD Liver Meeting, expanding on previous findings that showed semaglutide improved and sometimes completely resolved MASLD in HIV patients.
- Researchers at the University of North Carolina have developed microscopic soft robots called "DNA flowers" that can deliver drugs directly to target cells with precision. - These flower-shaped structures are created from hybrid crystals combining DNA with inorganic materials and can rapidly fold and unfold within seconds in response to environmental stimuli. - The DNA flowers can adapt their behavior based on conditions like temperature, acidity, or chemical signals, potentially enabling targeted drug delivery, biopsies, or blood clot removal. - The technology represents a breakthrough in bridging the gap between living systems and machines, with potential applications in medicine, environmental cleanup, and data storage.
- Arovella Therapeutics' proprietary CLDN18.2 chimeric antigen receptor demonstrated potent activity against pancreatic adenocarcinoma cells in preclinical testing at the University of North Carolina. - The CAR-T cells engineered with Arovella's patent-protected CLDN18.2 sequence performed comparably to CARsgen Therapeutics' leading construct currently under regulatory review in China. - The company plans to integrate its CLDN18.2 CAR into its invariant natural killer T (iNKT) cell platform, which may outperform conventional CAR-T cells in treating solid tumors. - Arovella is positioning itself as one of only a handful of companies pursuing CLDN18.2 CAR-iNKT therapies for pancreatic and gastric cancers.
- Novel type 1 and type 3 oral poliovirus vaccines (nOPV1 and nOPV3) showed strong safety profiles with no serious adverse events in a Phase 1 trial of 205 healthy adults. - The genetically stabilized vaccines achieved seroconversion rates of 86-100% and demonstrated comparable immune responses to existing Sabin-strain vaccines. - These vaccines are designed to reduce risks of vaccine-derived polioviruses and vaccine-associated paralytic poliomyelitis while supporting global polio eradication efforts. - Results provide sufficient evidence to advance both vaccine candidates into Phase 2 trials in target populations including children and infants.
- Digital inhalers can detect significant physiologic changes up to two weeks before COPD exacerbations occur, potentially enabling earlier clinical intervention. - The ProAir Digihaler captured three key metrics that changed significantly before acute exacerbations: inhalation volume, inhalation duration, and time to peak inhalation. - These physiologic changes preceded the typical increase in rescue inhaler use, suggesting patients may perceive symptoms after lung function deterioration begins. - The pilot study involved 40 current smokers with COPD and recorded 23 acute exacerbation events, demonstrating the technology's potential for remote patient monitoring.
- Researchers analyzed 678 AML patients and found that both gene mutations and leukemia cell maturity affect response to venetoclax plus hypomethylating agents treatment. - Patients with monocytic AML lacking the NPM1 mutation were nearly twice as likely to die from the disease compared to other patient groups. - The findings offer doctors a new risk classification system to better predict treatment response and guide personalized therapy decisions for AML patients. - This research represents a major step toward personalized medicine in AML by combining genetic and cellular factors to optimize treatment selection.
- Tonix Pharmaceuticals has initiated dosing in the Phase 2 OASIS trial evaluating TNX-102 SL for reducing acute stress reaction severity and acute stress disorder frequency following traumatic events. - The investigator-initiated study, sponsored by UNC and supported by a $3 million DoD grant, will enroll approximately 180 motor vehicle collision survivors through emergency departments across the U.S. - TNX-102 SL, a sublingual cyclobenzaprine formulation that has shown promise in improving sleep quality in PTSD patients, addresses a significant unmet need as no medications currently exist for immediate post-trauma treatment.
